Table 3.
Results of clinical trial for new agents targeting Tumor Microenvironment (TME).
| Trial name/code | Setting | Phase | Molecule | N° of NSCLC patients | ORR (CR) | DCR | Median PFS | Median OS |
|---|---|---|---|---|---|---|---|---|
| NCT02501096 | Pretreated (52% with ICIs) | II | Pembrolizumab + Lenvatinib | 21 | 33% | 82% | 5,9 mo | – |
| MRTX-500 (NCT02954991) | Pretreated with ICI (having had clinical benefit) | II | Nivolumab + sitravatinib (anti-VEGF et anti-TAM) | 68 non squamous | 16% | – | 6 mo | 15 mo |
| NCT03666143 | Pretreated (63% with ICI) | II | Tislelizumab (anti-PD-1) + sitravatinib | 75 | 17% | 85% | 5,5 mo | – |
| NCT03083041 | First line | II | Apatinib + camrelizumab | 25 non squamous | 40%PD-L1+40%PD-L1- | 92% | 11 mo PD-L1 + 9,7 mo PD-L1- |
NR |
| NCT03583086 | Pretreated, ICI primary resistant | II | Vorolanib + nivolumab | 15 | 7% | 57% | – | – |
| NCT04646330 | First line PD-L1+ | I | AK104 (bispecific Ab vs PD-1 and CTLA-4) + anlotinib | 8 | 62,5% | 100% | – | – |
| NCT02517398 | Pretreated, ICIs naive | I | Bintrafusp alfa (fusion protein anti PD-L+ & TGFβR) | 80 | 21,3% | 40% | – | – |
| NCT03774979 | First line PD-L1+ | I | SHR-1701 fusion protein anti PD-L1 & TGFβR | 52 | 44,2% | 73,1 | – | – |